PriceTargets.com logo

NASDAQ:CLDX - Celldex Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $35.50
  • Forecasted Upside: 38.56 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$25.62 As of 03/4/2021 11:57 AM ET
▼ -0.9 (-3.39%)
1 month | 3 months | 12 months
Get New Celldex Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CLDX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CLDX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$35.50
▲ +38.56% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Celldex Therapeutics in the last 3 months. The average price target is $35.50, with a high forecast of $36.00 and a low forecast of $35.00. The average price target represents a 38.56% upside from the last price of $25.62.
Buy
The current consensus among 3 contributing investment analysts is to buy stock in Celldex Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/11/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/10/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/4/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/2/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/4/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/1/2021HC WainwrightBoost Price TargetBuy$25.00 ➝ $36.00Low
i
2/23/2021HC WainwrightBoost Price TargetBuy$25.00 ➝ $36.00Medium
i
2/23/2021Cantor FitzgeraldBoost Price TargetOverweight$22.00 ➝ $35.00Medium
i
11/17/2020Lifesci CapitalReiterated RatingOutperformHigh
i
Rating by S. Slutsky at Lifesci Capital
10/19/2020HC WainwrightBoost Price TargetBuy$16.00 ➝ $25.00High
i
7/1/2020Cantor FitzgeraldBoost Price TargetOverweight$12.00 ➝ $18.00Medium
i
Rating by K. Kluska at Cantor Fitzgerald
6/12/2020Cantor FitzgeraldBoost Price TargetOverweight$8.00 ➝ $12.00High
i
Rating by K. Kluska at Cantor Fitzgerald
3/27/2020HC WainwrightReiterated RatingBuy$19.00 ➝ $16.00High
i
2/20/2020Cantor FitzgeraldInitiated CoverageOverweight$8.00High
i
Rating by K. Kluska at Cantor Fitzgerald
11/11/2019HC WainwrightReiterated RatingBuy$19.00Low
i
5/8/2019HC WainwrightSet Price TargetBuy$19.00High
i
Rating by Joseph Pantginis at HC Wainwright
4/2/2019HC WainwrightSet Price TargetBuy$19.00Medium
i
Rating by Joseph Pantginis at HC Wainwright
1/15/2019Bank of AmericaUpgradeNeutral ➝ BuyLow
i
11/19/2018HC WainwrightSet Price TargetBuy$30.00High
i
Rating by Joseph Pantginis at HC Wainwright
11/12/2018HC WainwrightReiterated RatingBuy$30.00High
i
Rating by Joseph Pantginis at HC Wainwright
8/10/2018Jefferies Financial GroupReiterated RatingHoldHigh
i
8/9/2018CowenReiterated RatingHoldLow
i
8/9/2018HC WainwrightSet Price TargetBuy$30.00High
i
Rating by Joseph Pantginis at HC Wainwright
6/4/2018HC WainwrightSet Price TargetBuy$30.00Low
i
Rating by Joseph Pantginis at HC Wainwright
5/17/2018HC WainwrightSet Price TargetBuy$30.00Low
i
Rating by Joseph Pantginis at HC Wainwright
5/10/2018CowenReiterated RatingHoldLow
i
4/17/2018Cantor FitzgeraldDowngradeOverweight ➝ Neutral$45.00Low
i
Rating by Mara Goldstein at Cantor Fitzgerald
4/16/2018CowenDowngradeOutperform ➝ Market PerformHigh
i
4/16/2018HC WainwrightSet Price TargetBuy$45.00High
i
Rating by Joseph Pantginis at HC Wainwright
3/8/2018SVB LeerinkReiterated RatingMarket Perform ➝ Market Perform$60.00 ➝ $45.00High
i
Rating by S. Fernandez at SVB Leerink LLC
3/8/2018HC WainwrightReiterated RatingBuy$150.00High
i
Rating by Joseph Pantginis at HC Wainwright
3/7/2018Cantor FitzgeraldReiterated RatingBuy$135.00High
i
2/9/2018HC WainwrightSet Price TargetBuy$150.00High
i
Rating by Joseph Pantginis at HC Wainwright
12/6/2017WBB SecuritiesReiterated RatingBuy$150.00Low
i
11/7/2017HC WainwrightReiterated RatingBuyN/A
i
Rating by J. Pantginis at HC Wainwright
9/26/2017Cantor FitzgeraldReiterated RatingBuy$135.00Low
i
8/9/2017HC WainwrightSet Price TargetBuy$150.00High
i
Rating by Joseph Pantginis at HC Wainwright
8/1/2017HC WainwrightReiterated RatingBuy ➝ Buy$150.00High
i
Rating by S. Ramakanth at HC Wainwright
6/29/2017AegisReiterated RatingBuyMedium
i
Rating by D. Yang at Aegis
6/6/2017CowenReiterated RatingBuyHigh
i
5/11/2017Jefferies Financial GroupReiterated RatingHold$60.00 ➝ $52.50High
i
3/21/2017AegisReiterated RatingBuyLow
i
Rating by J. Wittes at Aegis
3/15/2017Jefferies Financial GroupLower Price TargetHold$75.00 ➝ $60.00Medium
i
3/15/2017HC WainwrightReiterated RatingBuy$90.00Medium
i
Rating by S. Ramakanth at HC Wainwright
11/10/2016Roth CapitalReiterated RatingBuy$105.00N/A
i
Rating by Joseph Pantginis at Roth Capital
11/8/2016WedbushReiterated RatingNeutral$45.00N/A
i
11/8/2016Cantor FitzgeraldReiterated RatingBuy$135.00N/A
i
Rating by Mara Goldstein at Cantor Fitzgerald
11/7/2016AegisInitiated CoverageBuyN/A
i
11/2/2016Roth CapitalSet Price TargetBuy$105.00N/A
i
Rating by Joseph Pantginis at Roth Capital
10/10/2016Cantor FitzgeraldReiterated RatingBuy$135.00N/A
i
10/4/2016Brean CapitalInitiated CoverageBuy$240.00N/A
i
8/11/2016Jefferies Financial GroupReiterated RatingHold$60.00 ➝ $75.00N/A
i
Rating by Biren Amin at Jefferies Financial Group Inc.
8/9/2016WedbushReiterated RatingNeutral$45.00N/A
i
Rating by David Nierengarten at Wedbush
8/5/2016Jefferies Financial GroupBoost Price TargetHold$75.00N/A
i
Rating by Biren Amin at Jefferies Financial Group Inc.
6/7/2016CowenReiterated RatingOutperform$180.00N/A
i
Rating by Boris Peaker at Cowen Inc
5/6/2016WedbushReiterated RatingNeutral$45.00N/A
i
Rating by David Nierengarten at Wedbush
5/6/2016Jefferies Financial GroupReiterated RatingHold$60.00N/A
i
Rating by Biren Amin at Jefferies Financial Group Inc.
4/19/2016CowenReiterated RatingOutperform$180.00N/A
i
Rating by Boris Peaker at Cowen Inc
4/19/2016Roth CapitalReiterated RatingBuy$105.00N/A
i
Rating by Joseph Pantginis at Roth Capital
3/8/2016Roth CapitalReiterated RatingBuyN/A
i
Rating by Joseph Pantginis at Roth Capital
3/8/2016Brean CapitalReiterated RatingBuy$360.00N/A
i
Rating by Jonathan Aschoff at Brean Capital
3/8/2016HC WainwrightLower Price TargetBuy$375.00 ➝ $90.00N/A
i
Rating by Swayampakula Ramakanth at HC Wainwright
3/8/2016CowenReiterated RatingOutperform$420.00 ➝ $180.00N/A
i
Rating by Boris Peaker at Cowen Inc
3/7/2016Jefferies Financial GroupDowngradeBuy ➝ Hold$465.00 ➝ $60.00N/A
i
3/7/2016SVB LeerinkDowngradeOutperform ➝ Market Perform$450.00 ➝ $60.00N/A
i
3/7/2016WedbushDowngradeOutperform ➝ Neutral$60.00N/A
i
Rating by D. Nierengarten at Wedbush
3/7/2016OppenheimerDowngradeOutperform ➝ Market PerformN/A
i
3/7/2016GuggenheimDowngradeBuy ➝ NeutralN/A
i
(Data available from 3/4/2016 forward)
Celldex Therapeutics logo
Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of immunotherapies and other cancer-targeting biologics. It develops CDX-1140, an agonist human monoclonal antibody, which is being studied as a single-agent and in combination with CDX-301 in a Phase I dose-escalation study in metastatic solid tumors and B cell lymphomas; CDX-3379, a monoclonal antibody designed to block the activity of ErbB3 that is in an early Phase II study in advanced head and neck squamous cell cancer in combination with Erbitux; CDX-0159, a Phase I monoclonal antibody that binds the KIT receptor and inhibits its activity; and CDX-527, a bispecific antibody that uses anti-PD-L1 and CD27 human antibodies to couple CD27 co-stimulation with blockade of the PD-L1/PD-1 pathway. The company also holds exclusive rights to CDX-301 and CD40 ligand, which are immune modulating molecules that increase the numbers and activity of immune cells that control immune responses. Celldex Therapeutics, Inc. has research collaboration and license agreements with University of Southampton; Amgen Inc.; Yale University; and MedImmune, LLC. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
Read More

Today's Range

Now: $25.62
$24.38
$26.68

50 Day Range

MA: $22.77
$17.53
$29.91

52 Week Range

Now: $25.62
$1.50
$30.17

Volume

12,227 shs

Average Volume

618,800 shs

Market Capitalization

$1.01 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.96

Frequently Asked Questions

What sell-side analysts currently cover shares of Celldex Therapeutics?

The following equities research analysts have issued stock ratings on Celldex Therapeutics in the last year: Cantor Fitzgerald, HC Wainwright, Lifesci Capital, and Zacks Investment Research.
View the latest analyst ratings for CLDX.

What is the current price target for Celldex Therapeutics?

2 Wall Street analysts have set twelve-month price targets for Celldex Therapeutics in the last year. Their average twelve-month price target is $35.50, suggesting a possible upside of 18.7%. HC Wainwright has the highest price target set, predicting CLDX will reach $36.00 in the next twelve months. Cantor Fitzgerald has the lowest price target set, forecasting a price of $35.00 for Celldex Therapeutics in the next year.
View the latest price targets for CLDX.

What is the current consensus analyst rating for Celldex Therapeutics?

Celldex Therapeutics currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CLDX will outperform the market and that investors should add to their positions of Celldex Therapeutics.
View the latest ratings for CLDX.

What other companies compete with Celldex Therapeutics?

Other companies that are similar to Celldex Therapeutics include Amgen, Gilead Sciences, Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Biogen, Alexion Pharmaceuticals, Seagen, Exact Sciences, Alnylam Pharmaceuticals, Incyte, BioMarin Pharmaceutical, Novavax, Repligen, Neurocrine Biosciences and Ionis Pharmaceuticals.

How do I contact Celldex Therapeutics' investor relations team?

Celldex Therapeutics' physical mailing address is 53 FRONTAGE ROAD SUITE 220, HAMPTON NJ, 08827. The biopharmaceutical company's listed phone number is 908-200-7500 and its investor relations email address is [email protected] The official website for Celldex Therapeutics is www.celldex.com.